MaaT Pharma's Marketing Application for MaaT013 Faces Setback

On June 30, 2026, First Berlin Equity Research released an update regarding MaaT Pharma SACA, following the European Medicines Agency’s (EMA) negative stance on MaaT013's Marketing Authorisation Application. The decision, informed by the Committee for Medicinal Products for Human Use (CHMP), echoes previous apprehensions about attributing clinical benefits solely to MaaT013 in acute Graft-versus-Host Disease due to concurrent therapies. Analyst Christian Orquera maintained the 'under review' status for both rating and target price.

Despite this regulatory hurdle, MaaT Pharma plans to appeal by seeking re-examination of the CHMP decision and consulting a Scientific Advisory Group specializing in haematology. This process is likely to play a critical role in the company's next steps, with the second CHMP opinion anticipated in September. Investment perspectives remain unchanged, with financial viability sustained until November 2026.